Correlation analysis confirms differences in antioxidant defence in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication.
The activities of antioxidant defence enzymes were determined in erythrocytes isolated from types I and II schizophrenic male patients and from healthy controls. Significant differences in superoxide dismutase (SOD) activity (type I: 3284+/-577; type II: 2959+/-697 compared with controls: 3778+/-577; analysis of variance (ANOVA) P<0.001), catalase (CAT) activity (type I: 17.8+/-1.8 compared to type II: 19.2+/-1.5 and both compared with controls: 19.2+/-1.5; ANOVA P<0.05), glutathione peroxidase (GSH-Px) activity (controls: 17.8+/-2.3; type I: 13.9+/-2.9 and type II: 11.6+/-1.9; ANOVA P<0.001) as well as in glutathione reductase (GR) activity (controls: 5,0+/-0.8; type I: 4.3+/-0.9 and type II: 4.5+/-0.8; ANOVA P<0.01) were apparent. Correlation analysis of antioxidant defence enzymes showed significant negative correlation between GSH-Px and CAT activities (P<0.01) in type I patients. In type II patients, GSH-Px activity was significantly positively correlated with GR (P<0.01). Canonical discriminant analysis separated type I and type II patients from controls (and among each other) with a high degree of certainty according to the overall group composition of antioxidant defence enzymes. Our results indicate differences in the composition of antioxidant defence between controls and anti-psychotic treated type I and type II patients with a possible negative feedback influence on the pathological process, which could provide a rationale for applying antioxidants during schizophrenic therapy.
Miljević
Cedo
C
Institute of Mental health, Palmotićeva 37, Belgrade, Serbia.
Nikolić-Kokić
Aleksandra
A
Saicić
Zorica S
ZS
Milosavljević
Maja
M
Blagojević
Dusko
D
Tosevski
Dusica Lecić
DL
Jones
David R
DR
Spasić
Mihajlo B
MB
D000328:Adult; D000704:Analysis of Variance; D000975:Antioxidants / Q000378:metabolism*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D002374:Catalase / Q000097:blood; D002746:Chlorpromazine / Q000627:therapeutic use*; D005979:Glutathione Peroxidase / Q000097:blood; D005980:Glutathione Reductase / Q000097:blood; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000097:blood / Q000145:classification / Q000188:drug therapy; D013482:Superoxide Dismutase / Q000097:blood; D055815:Young Adult
D000975:Antioxidants; D014150:Antipsychotic Agents; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D002746:Chlorpromazine